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Factors Associated with Quality of Life in
Chronic Hepatitis C Patients Who Received
Interferon Plus Ribavirin Therapy
Shu-Chuan Chang,1 Wang-Sheng Ko,2 Shun-Sheng Wu,3 Cheng-Yuan Peng,4
Sheng-Shun Yang1,5,6*
Background/Purpose: Antiviral treatment leading to impaired quality of life in chronic hepatitis C patients
has been reported in the West. To promote high quality care, we explored the quality of life in Taiwanese
chronic hepatitis C patients treated with antiviral therapy by means of comparing quality of life, social
support and its factors.
Methods: One hundred and fifteen patients with chronic hepatitis C, enrolled from hospitals in Central
Taiwan, were treated with interferon plus ribavirin. A structured questionnaire was used for data collection,
including the Hepatitis Quality of Life Questionnaire (HQLQ), Inventory of Socially Supportive Behaviors
(ISSB) and clinical demographics. The data were analyzed by the methods of means, correlation and 
regression.
Results: The study patients included 60 men (52.2%) and 55 women (47.8%), with 98 (85.2%) older than
40 years. The drug expenses of 71 (61.7%) patients were paid for by the Bureau of National Health Insurance
of Taiwan. The patients had a low mean HQLQ score of 58.13 ± 17.21. Three scales which had HQLQ scores
below 50 were general health perceptions (49.39), vitality (49.32) and role disability: physical (47.48).
The mean ISSB score was 71.15 ± 19.61. Only financial stress (p = 0.006) had significant difference in HQLQ.
Treatment duration (r =−0.23) correlated negatively with the general health domain of HQLQ, and tangible
support (r = −0.21) correlated negatively with HQLQ scales. Financial stress and tangible support were 
significant predicting variables for HQLQ.
Conclusion: The study found that patients with chronic hepatitis C who received interferon plus ribavirin
therapy had poor quality of life during the treatment period. There was significant difference among 
patients with different financial stress, and a negative relationship between tangible support and hepatitis
quality of life. Financial stress and tangible support are predictors of quality of life for all subjects. The 
results of this study might assist healthcare personnel to comprehend the quality of life and its related 
factors in patients with chronic hepatitis C treated with antiviral therapy. [J Formos Med Assoc 2008;
107(6):454–462]
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About 2–4% of the general population in Taiwan
are infected with the hepatitis C virus (HCV), and
anti-HCV positivity has been detected in up to
30–60% in some counties;1,2 85% of infected in-
dividuals progress to chronic hepatitis C (CHC).3
Over time, approximately 35% of patients with
CHC will progress to cirrhosis and 20% of patients
will develop hepatocellular carcinoma following
exposure to HCV.4
Interferon (IFN) plus ribavirin therapy is cur-
rently approved for the treatment of patients with
CHC.5,6 The treatment, however, produces varying
degrees of adverse events such as fatigue, myalgia,
influenza-like symptoms, and alterations in mood,
inability to concentrate, and change in libido,
which may negatively affect a patient’s vitality,
social interaction, and ability to perform work and
other activities, and even lead to discontinuation
of therapy.7–9
The negative influences on the quality of life
(QOL) of treated CHC patients are great. Several
cross-sectional and longitudinal studies have
demonstrated the negative impact of CHC on
health-related QOL (HRQOL). Patients with CHC
performed worse on the generic and disease-
specific scales of HRQOL domains than patients
with other chronic diseases.10–12 The three major
factors associated with poor QOL are symptoms
associated with CHC, treatment including IFN plus
ribavirin, and the disease itself. Other factors that
may affect HRQOL include non-modifiable factors
such as gender, ethnicity and age.13 It has been
demonstrated that IFN-based treatment in CHC
patients led to them experiencing negative impacts
on HRQOL using both qualitative and quantitative
measurements.14,15
The accumulated evidence suggests that social
support is a means of buffering the negative health
outcomes that result from the stress of serious
illness.16 The commonly held assumptions re-
garding social support, in the form of support
groups, suggest that supportive relationships en-
hance wellbeing, promote the exchange of infor-
mation, education, and emotional support, and
promote positive adaptation to chronic diseases.17
Studies on the relationship between social support
and QOL in HIV-infected persons have demon-
strated a significant association. Social support was
significantly associated with all QOL domains.18,19
A recent study conducted by Jessop et al reported
that patients stated the support they received from
“hepatitis support group” was instrumental in
their ability to continue therapy (despite unpleas-
ant adverse events), make important lifestyle
changes, adopt more appropriate coping strategies,
and share information more readily with health-
care providers, family and friends.20
To our knowledge, research on liver disease,
especially that on hepatitis B virus infection, has
shown a great deal of progress and achievement
in the past, whereas published articles concerning
nursing care or QOL for liver disease are very rare
in Taiwan. Most studies that used the modified
Chinese version of the QOL Questionnaire that
originated from Ferrans and Powers have shown
a moderate degree of QOL in the studied sub-
populations of patients with hepatocellular car-
cinoma, post-liver transplantation, and aboriginal
patients with cirrhosis.21–23 The goals of this study
were to: (1) assess QOL and level of social support
in patients with CHC in Taiwan; (2) investigate
the relationships among QOL, social support and
clinical factors in these patients.
Material and Methods
This study used a cross-sectional descriptive and
correlational design and purposive sampling. We
used questionnaires to conduct interviews of CHC
patients in the outpatient clinics of three medical
centers and one regional teaching hospital in
central Taiwan. The research protocols were 
approved by coordinated physicians.
CHC patients were defined as those who had
both HCV antibody and HCV RNA positive for
more than 6 months, elevated serum alanine
aminotransferase (ALT) level, and confirmation
by liver histology in most participants. All patients
undergoing pegylated IFN plus ribavirin therapy
were invited to complete the questionnaires 
during treatment. We interviewed each enrolled
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individual during their outpatient clinic visit be-
tween July 1 and September 31, 2006, and assisted
them in filling out the questionnaires, including
the demographic questionnaire, Hepatitis Quality
of Life Questionnaire (HQLQ) and Inventory of
Socially Supportive Behaviors (ISSB) questionnaire.
A total of 140 patients were contacted. Among
them, 121 patients agreed to participate and gave
written informed consent. The response rate of this
survey was 86%. Finally, there were 115 completed
surveys analyzed.
The HQLQ has been used in recent studies of
HRQOL in CHC patients.11,24 The questionnaire
contains 17 multi-item scales in four categories:
(1) a 36-item generic core (SF-36); (2) generic
items selected to augment the SF-36 in measuring
four of the eight SF-36 concepts; (3) additional
generic scales; and (4) two hepatitis-specific
scales. We modified the questionnaire and trans-
lated it into Chinese which provides scores across
12 dimensions (physical functioning, role disabil-
ity: physical, bodily pain, general health, vitality,
social functioning, role disability: emotional, men-
tal health, positive wellbeing, sleep somnolence,
health distress due to CHC and limitations due to
CHC) as a tool for study. The scales were all scored
from 0 to 100 metric, with higher scores indicat-
ing better health. The tool has been proven to
have a high degree of acceptability and data qual-
ity by many researchers. The internal consistency
of the scales shown by Cronbach’s α was greater
than 0.94 in this study.
The ISSB contains four types of support: emo-
tional, appraisal, informational and tangible.25
The ISSB is a 15-item questionnaire that asks re-
spondents to rate on a 4-point scale. Raw scores
are then linearly transformed to a 0 to 100 scale,
with 0 representing the lowest possible score and
100 the highest possible score. The reliability co-
efficient of the internal consistency for the total
scale was 0.89.
Demographic items including age, gender,
marital status, education, current employment,
and baseline clinical characteristics (HCV geno-
type, serum ALT level on interview, comorbid ill-
nesses) were obtained from medical records.
Data analysis
Data were analyzed using SPSS version 10.0 (SPSS
Inc., Chicago, IL, USA). Normal distribution and
homogeneity of the data in this study were con-
firmed by QQ plot and Levene statistics. The statis-
tical strategies performed included the following:
(1) descriptive analysis of the whole sample
(n = 115) in terms of demographics, HQLQ and
ISSB; (2) bivariate associations were estimated
with Pearson’s product-moment correlation coef-
ficients for continuous variables; (3) variable cor-
relation assumptions were tested using ANOVA;
and (4) stepwise regression analysis was used to
model each domain score separately including
clinical, demographic and social support inde-
pendent variables for the different domains of
HQLQ while controlling for other variables in
the model.
Results
Clinical characteristics and demographic
data
One hundred and fifteen patients received inter-
views and filled out questionnaires during the
study period. The demographic data and clinical
characteristics of the 115 study subjects are sum-
marized in Table 1. There were 60 men (52.2%)
and 55 women (47.8%); 98 (85.2%) were older
than 40 years. Mean age was 51.59 ± 11.45 years
(range, 20–72 years). The majority (79.1%) of
the patients had education below senior high
school; 95 (82.6%) patients were married and
lived with their family. Most of these patients
(n = 79, 60%) were currently employed and most
(n = 30, 26%) were laborers. The majority had
HCV genotype 1b (62.6%) and a non-cirrhotic
histological diagnosis (76.5%). Most (63.5%)
patients had no comorbid illness. The mean treat-
ment duration on interview was 17.59 ± 10.53
weeks, while the treatment duration of 50 (43.5%)
patients ranged from 13 to 24 weeks. Mean ALT
level was 49.94 ± 55.89 U/L (range, 11–509 U/L)
and 59.1% were normal on interview. The treat-
ment fee of 71 (61.7%) patients was fully covered
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by the Bureau of the National Health Insurance
(BNHI) of Taiwan; nine patients were partially
covered because they had to receive extended
therapy, for which they had to pay themselves. 
A total of 68.7% patients complained of a certain
degree of financial stress.
Impact of treatment on HQLQ
Mean HQLQ domain scores are listed in Table 2.
Patients had a low mean HQLQ score of 58.13 ±
17.21. The results showed a mean score greater
than 70 for physical functioning, whilst scores were
below 63 in the other 11 domains. There were three
scales that had scores below 50: general health
perceptions (49.39), vitality (49.32), and role dis-
ability: physical (47.48). This indicates that most
patients perceived that they had poor personal
health, and felt tired and down in their daily ac-
tivities and life throughout the period of antiviral
treatment for CHC. Most scales had a score of 0
except for the three domains of general health
perceptions (minimal value = 5), general mental
health (minimal value = 12) and positive wellbe-
ing (minimal value = 11). This finding indicates
that there was low HQLQ in CHC patients during
treatment.
Social support
Mean ISSB score was 71.15±19.61 (range, 20–100).
Social support measures showed that patients as
a whole perceived themselves as having relatively
good support, with 76.91 ± 23.51 for appraisal,
74.86 ± 21.29 for emotional, 70.03 ± 23.81 for in-
formational, and 62.80 ± 27.06 for tangible (see
Table 3), with the most support being perceived
Table 1. Distribution of clinical characteristics and
demographic data in 115 patients*
Gender
Male 60 (52.2)
Female 55 (47.8)
Age (yr)
≤ 40 17 (14.8)
41–50 30 (26.1)
51–60 44 (38.3)
61–72 24 (20.9)
Education level
Elementary school and below 45 (39.1)
Junior/senior high school 46 (40.0)
College and above 24 (20.9)
Marital status
Single 13 (11.3)
Married 95 (82.6)
Widowed or divorced 7 (6.1)
Occupation
Not currently employed 46 (40.0)
Farmer 5 (4.3)
Laborer 30 (26.1)
Businessman 16 (13.9)
Other 18 (15.7)
Financial stress
Severe 22 (19.1)
Moderate 33 (28.7)
Mild 24 (20.9)
None 36 (31.3)
BNHI coverage
Full 62 (53.9)
Partial 9 (7.8)
None 44 (38.3)
Histological diagnosis
Non-cirrhosis 88 (76.5)
Cirrhosis 27 (23.5)
Genotype of virus
1a 4 (3.5)
1b 72 (62.6)
2a 19 (16.5)
2b 7 (6.1)
Missing data 13 (11.3)
Comorbid illness
None 73 (63.5)
Medical 26 (22.6)
Other 16 (13.9)
(Contd.)
Treatment duration (wk) 17.59 ± 10.53
≤ 4 12 (10.4)
5–12 29 (25.2)
13–24 50 (43.5)
25–48 24 (20.9)
ALT level (U/L) 49.94 ± 55.89
< 40 68 (59.1)
41–200 47 (40.9)
*Data presented as n (%) or mean ± standard deviation. BNHI =
Bureau of the National Health Insurance of Taiwan; ALT = alanine
aminotransferase.
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in the area of appraisal and emotional support.
According to results from the ISSB, patients re-
ported the lowest scores on tangible support.
Relationships among QOL, social support
and clinical factors
Except for financial stress (p = 0.006), there were
no significant differences in QOL among pa-
tients with various demographic and clinical
characteristics in HQLQ. Results from Scheffé’s
posteriori comparison showed that HQLQ was
significantly different in patients with different
levels of financial stress. Mean HQLQ score was
significantly higher in patients with no financial
stress (mean = 65.46) than in those with moderate
(mean=54.13) and severe (mean=51.22) financial
stress (p < 0.05) (Table 4).
Of the clinical characteristics and demo-
graphic data, only treatment duration (r = −0.23)
correlated negatively with the general health do-
main of the HQLQ (Table 5). The most patients
perceived poor personal health concerning long
antiviral treatment duration for their illness. ALT
level showed no significant correlation with any
domain of the HQLQ. As shown in Table 5, all
social support subscales, except tangible support,
had no significant correlation with the scores of
the HQLQ subscales. Tangible support correlated
negatively with the scores of HQLQ subscales on
social functioning (r = −0.24), physical function-
ing (r =−0.24), mental health (r =−0.20) and total
score (r = −0.21).
Predictors of total HQLQ
Stepwise regression analysis was used to predict
total HQLQ score. The relatively independent vari-
ables were chosen in stepwise regression, such as
the clinical demographic variables (financial stress
and treatment duration), and social support in-
dependent variables. Table 6 shows the β coeffi-
cient obtained from each independent variable
and the adjusted R2 values obtained from each
Table 2. Hepatitis Quality of Life Questionnaire (HQLQ) domain scores in 115 patients
Minimum value Maximum value Mean ± SD
SF36 scales
Physical functioning 0 100 76.26 ± 20.55
Role disability: physical 0 100 47.48 ± 34.48
Bodily pain 0 100 63.13 ± 23.78
General health perceptions 5 100 47.39 ± 20.46
Vitality 0 100 49.32 ± 22.18
Social functioning 0 87.5 53.75 ± 18.60
Role disability: emotional 0 100 57.61 ± 36.45
General mental health 12 100 60.66 ± 20.16
Additional generic scales
Positive wellbeing 11 100 52.35 ± 20.84
Sleep somnolence 0 100 62.96 ± 23.63
CHC-specific scales
CHC distress 0 100 62.17 ± 28.11
CHC limitations 0 100 62.55 ± 24.94
Summary score of HQLQ 9.62 95.95 58.13 ± 17.21
SD = standard deviation; SF36 = short-form 36; CHC = chronic hepatitis C.
Table 3. Descriptive analysis of social support
Type of Minimum Maximum 
Mean ± SD
support value value
Emotional 8.3 100 74.86 ± 21.29
Appraisal 0 100 76.91 ± 23.51
Informational 0 100 70.03 ± 23.81
Tangible 0 100 62.80 ± 19.61
SD = standard deviation.
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Table 4. Analysis of variance for clinical characteristics and demographic data in Hepatitis Quality of Life
Questionnaire (HQLQ)
Mean ± SD F p
Gender 1.61 0.21
Male 60.08 ± 17.92
Female 56.00 ± 16.30
Age (yr) 2.02 0.12
≤ 40 65.52 ± 14.91
41–50 55.65 ± 17.42
51–60 55.19 ± 17.85
61–72 61.39 ± 16.12
Education level 0.17 0.84
Elementary school and below 57.48 ± 17.01
Junior/senior high school 57.82 ± 16.30
College and above 59.97 ± 19.74
Marital status 1.08 0.34
Single 63.96 ± 19.18
Married 57.07 ± 17.01
Widowed or divorced 61.75 ± 15.92
Occupation 0.89 0.47
Not currently employed 55.01 ± 17.26
Farmer 66.02 ± 19.60
Laborer 60.50 ± 16.00
Businessman 60.95 ± 19.90
Other 57.48 ± 16.11
BNHI coverage 0.02 0.98
Full 58.04 ± 15.89
Partial 59.16 ± 22.08
None 58.05 ± 18.34
Histological diagnosis 0.02 0.90
Non-cirrhosis 58.02 ± 16.29
Cirrhosis 58.51 ± 17.58
Genotype of virus 0.98 0.41
1a 56.66 ± 10.16
1b 58.60 ± 17.88
2a 51.60 ± 16.66
2b 58.69 ± 12.40
Comorbid illness 0.89 0.41
None 58.33 ± 17.20
Medical 60.55 ± 15.40
Other 53.30 ± 20.03
ALT level (U/L) 1.86 0.18
< 40 56.29 ± 17.76
41–200 60.71 ± 16.25
Financial stress 4.32 0.006
Severe 51.22 ± 18.60
Moderate 54.13 ± 16.06
Mild 58.97 ± 15.53
None 65.46 ± 17.21
Posteriori comparison None > Severe
None > Middle
SD = standard deviation; BNHI = Bureau of the National Health Insurance of Taiwan; ALT = alanine aminotransferase.
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regression model, which is a measure of the pro-
portion of variance of the dependent variable ac-
counted for in the regression model. The significant
predicting factors of HQLQ were different financial
stress (β= 0.29) and tangible support (β=−0.22).
The regression models explained 13% of the vari-
ance in total HQLQ score. Regression analysis with
HQLQ showed a significant positive correlation
with no financial stress and a negative correlation
with tangible support.
Discussion
Previous reports from Western countries have 
focused on comparison of HRQOL before and
after antiviral therapy in CHC patients, which re-
vealed that the HRQOL of CHC patients could
be improved through aggressive antiviral therapy.
But therapeutic discomfort during the treatment
period could impair patient compliance and will-
ingness to continue with antiviral therapy. A neg-
ative impact on QOL in CHC patients has been
well documented in Western populations.12,13,26
To the best of our knowledge, there have been
only two reports describing the impact of antivi-
ral therapy on the QOL of Taiwanese patients
with CHC.27,28 Those reports demonstrated that
QOL was significantly poorer in patients receiv-
ing antiviral treatment as compared with before
therapy. Our results also showed that the mean
scores of QOL were significantly reduced among
CHC patients during antiviral treatment. Patients
had lower scores in the role-physical, general health
and vitality domains. This finding is almost con-
sistent with those of Ware et al12 and Kang et al,27
who reported that the scales most affected by treat-
ment were role disability: physical, general health,
vitality, and mental health domains. The findings
of these studies indicate no ethnic differences
Table 5. Pearson’s correlation coefficients between quality of life and social support and clinical
characteristics
Support ALT Treatment
Emotional Appraisal Informational Tangible level duration
Physical functioning −0.13 0.08 −0.08 −0.24* −0.07 −0.18
Role disability: physical −0.09 −0.04 −0.12 −0.16 −0.01 −0.17
Bodily pain −0.13 0.09 −0.02 −0.18 −0.09 −0.02
General health perception −0.08 −0.10 −0.08 −0.04 −0.01 −0.23*
Vitality −0.08 −0.00 −0.16 −0.15 −0.08 −0.05
Social functioning −0.04 0.13 −0.09 −0.24* −0.05 0.05
Role disability: emotional −0.12 −0.02 −0.13 −0.18 −0.10 −0.07
General mental health −0.04 0.00 −0.09 −0.20* −0.03 −0.06
Positive wellbeing −0.03 0.06 −0.07 −0.11 −0.04 −0.03
Sleep somnolence −0.04 −0.02 −0.06 −0.07 −0.10 0.11
CHC distress −0.18 −0.04 −0.02 −0.09 −0.04 −0.12
CHC limitations 0.01 0.17 0.12 −0.08 0.01 0.00
Total of HQLQ −0.12 0.03 −0.10 −0.21* −0.09 −0.10
*p < 0.05. ALT = alanine aminotransferase; CHC = chronic hepatitis C; HQLQ = Hepatitis Quality of Life Questionnaire.
Table 6. Stepwise regression for predictive factors on Hepatitis Quality of Life Questionnaire
Model Variables entered R2 B β F p
1 Financial stresses (none) 0.08 10.52 0.29 9.73 0.003
2 Tangible support 0.13 −4.71 −0.22 8.13 0.010
concerning impairment of QOL in CHC patients
treated with antiviral agents.
Among the demographic variables examined,
the most influential factor was self-perceived fi-
nancial stress. Our study illustrated that patients
with moderate to severe financial stresses have
significantly poorer QOL during treatment com-
pared to those without financial stress. Because
some patients’ treatment fee was covered by the
BNHI for 6 months, they needed extra self-pay-
ment once extension therapy was required. The
loading of heavy medical expenses can affect QOL
negatively. There were no significant differences
in the other variables. This finding was consistent
with that of Chen,28 but discrepant from Miller
et al’s finding which showed that there were dif-
ferences among gender, age and employment
status.29 Their study also showed that there was
no significant association between QOL and serum
ALT levels.29 Our study found no evidence of cor-
relation between the two either. Treatment dura-
tion correlated negatively with the general health
perception domain, indicating that most patients
perceived poor personal health with regard to long
antiviral treatment period for their illness.
Social support measures showed that the par-
ticipants perceived themselves to be relatively well
supported in terms of appraisal and emotional
support, while most perceived themselves to be
poorly supported in tangible support. The findings
are consistent with Chen’s report28 but contrary
to some studies in HIV-infected persons which
demonstrated that the most positive support per-
ceived was in tangible support while the least was
in appraisal support.18,19
The subscale that correlated negatively with
HQLQ measures was tangible support. Because the
questionnaire items for tangible support included
daily care and financial assistance, our finding can
be explained by less tangible support requirement
or less financial stress in patients who had higher
HQLQ scores. Studies on the relationship between
social support and QOL in HIV-infected persons
have demonstrated a significant positive associa-
tion.18,19 Our results did not show a significant
positive correlation between social support and
HQLQ in CHC patients in Taiwan. Similar find-
ings were reported by Chen28 and Miller et al29
in CHC patients who received IFN plus ribavirin.
In addition, Jessop et al reported that being in a
hepatitis support group (which consisted of health-
care providers, family members and friends) had
beneficial effects on patients’ HRQOL.20 Our study
indicates that there is no formal social support
group for this patient population in Taiwan; the
principal support for CHC patients comes from
family members and hepatitis study nurses.
We found that QOL was poor in CHC patients
treated with antiviral therapies. Maintaining an
acceptable HRQOL on therapy is crucial to patient’s
adherence to treatment. HRQOL issues should
be considered in conjunction with safety and 
efficacy in choosing the optimal therapy for the
treatment of CHC patients.
In summary, the exploratory study presented
here indicates that there is no strong association
between social support and HQLQ in CHC pa-
tients in Taiwan. Also, there was no relationship
between clinical demographic characteristics and
HQLQ in CHC patients treated with IFN plus rib-
avirin. Financial stress has a significant impact on
HQLQ throughout the period of antiviral therapy.
The data may help healthcare personnel to un-
derstand more about patients’ HRQOL during
treatment and the factors that influence it. In the
meantime, this study demonstrates that awareness
of patients’ financial stress is equally important to
patients’ subjective feelings of wellbeing during
nursing care for CHC patients receiving antiviral
treatment. Nursing personnel may play a role in
assisting CHC patients to assess antiviral treatment
information, apply for financial support either
from the BNHI or from charities, especially for
patients who need extended therapy.
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